Voir la source de Title Loaded From File

The authors greatly appreciate the participation of the dental practitioners in Hong Kong and the TPG students (MDS Implant Dentistry) at the University of Hong Kong for their willingness to participate in the survey. This study received no financial support from commercial or other bodies aside from the Faculty of Dentistry, The University of Hong Kong, and the Clinical Research Foundation (CRF) for the Promotion of Oral Health, Brienz, Switzerland. ""Y. De Waal University of Groningen, University Medical Center Groningen, Groningen, the Netherlands Background Peri-implantitis is an infectious disease that resides in the mucosa surrounding dental implants and affects the supporting bone. Many different treatment strategies for peri-implantitis have been suggested. However, little is known about factors that predict the outcome [http://www.selleckchem.com/screening/natural-product-library.html HCS assay] of peri-implantitis treatment. Knowing these factors could lead to improved treatment strategies for peri-implantitis. Aim/Hypothesis The objective of this retrospective cohort study was to identify factors associated with success or failure of resective surgical peri-implantitis treatment. Material and methods Data were obtained from two previously conducted randomized controlled trials evaluating different methods for implant surface decontamination during resective peri-implantitis treatment. Seventy-four patients (187 implants) with peri-implantitis were treated by one oral- and maxillofacial surgeon with apically re-positioned flap, bone recontouring and surface debridement and decontamination. Demographic, [https://en.wikipedia.org/wiki/Aldosterone Aldosterone] clinical and radiographical parameters were recorded before treatment (baseline) and at 3, 6 and 12?months after treatment. Treatment was considered successful if the following criteria were met: (1) absence of progressive bone loss, (2) absence of suppuration, (3) bleeding [http://www.selleckchem.com/products/cobimetinib-gdc-0973-rg7420.html GDC-0973 mw] on probing at �� 50% of sites and (4) probing pocket depth